|
US cost-effectiveness of saxagliptin in type 2 diabetes mellitus |
Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. American Journal of Pharmacy Benefits 2012; 4(1): 20-28 Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans AccessionNumber 22012018472 Date bibliographic record published 14/01/2013 |
|
|
|